<DOC>
	<DOCNO>NCT00000954</DOCNO>
	<brief_summary>To determine toxicity response treatment cytotoxic chemotherapy use doxorubicin ( Adriamycin ) , bleomycin , vincristine ( DBV ) advance AIDS-related Kaposi 's sarcoma combination either didanosine ( ddI ) zalcitabine ( dideoxycytidine ; ddC ) . AIDS patient extensive Kaposi 's sarcoma require treatment effective cytotoxic agent reduce tumor burden , also require treatment possibly effective antiretroviral agent ddI ddC ameliorate ( delay ) development opportunistic infection .</brief_summary>
	<brief_title>A Study Chemotherapy Plus ddI ddC Treatment AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>AIDS patient extensive Kaposi 's sarcoma require treatment effective cytotoxic agent reduce tumor burden , also require treatment possibly effective antiretroviral agent ddI ddC ameliorate ( delay ) development opportunistic infection . In Phase I , eligible patient advance Kaposi 's sarcoma randomly assign either ddI ddC combination DBV chemotherapy . On average , patient receive 12-44 week combine chemotherapy antiretroviral therapy . If vincristine delete Phase I excess neurotoxicity , administer part combination chemotherapy treatment continue Phase II study . The Phase II trial proceeds least six cycle ( 12 week ) DBV complete six patient enrolled Phase I , overall evaluation tolerance combination treatment plan complete . Study medication administer Phase I , possible deletion vincristine . All patient complete DBV chemotherapy complete partial response stable disease continue receive originally assign investigational antiretroviral drug ( ddC ddI ) additional 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Prophylaxis Pneumocystis carinii pneumonia patient CD4 cell count &lt; 200 cells/mm3 . Allowed : Chemoprophylaxis candidiasis , MAC , herpes simplex . Up 14day course metronidazole . Recombinant erythropoietin . Granulocytemacrophage colony stimulate factor ( GMCSF ) granulocyte colony stimulate factor ( GCSF ) patient ANC &lt; 1000 cells/mm3 . Isoniazid treatment tuberculosis , permission protocol chair , give conjunction pyridoxine . Patients must : HIV infection . Kaposi 's sarcoma . For patient &lt; 18 year age : consent parent guardian . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Opportunistic infection require treatment myelosuppressive antibiotic ( unless GCSF GMCSF ) . Other active malignancy except basal cell carcinoma skin situ cervical carcinoma . Prior history current clinical evidence peripheral neuropathy ( = &gt; grade 1 ) , pancreatitis , intractable diarrhea , active seizure disorder control antiseizure medication . Significant pulmonary insufficiency ( exertional dyspnea minimal exertion , except due pulmonary Kaposi 's sarcoma ) cardiac insufficiency ( New York Heart Association status &gt; 2 ) . Neuropsychiatric history alter mental status would prevent informed consent would permit compliance protocol . Concurrent Medication : Excluded : Myelosuppressive antibiotic ( unless GCSF GMCSF ) . Investigational agent drug available treatment IND use FDA sanction indication , antiviral , immunomodulating antitumor drug . Drugs associate peripheral neuropathy ( ddI , ddC , vincristine ) , include hydralazine , disulfiram , nitrofurantoin , cisplatin , diethyldithiocarbamate , gold , rifampin , chloramphenicol , clioquinol , ethambutol , ethionamide , glutethimide , sodium cyanate , thalidomide . Patients follow prior condition symptom exclude : Neuropsychiatric history alter mental status would prevent informed consent would permit compliance protocol . Prior Medication : Excluded : Systemic treatment doxorubicin , bleomycin , vincristine . Antitumor ( Kaposi 's sarcoma ) drug within 7 day study entry . Any investigational drug ( drug available treatment IND use FDA sanction indication ) within 14 day study entry . Neurotoxic drug ( ddI ddC ) within 30 day study entry . Intralesional injection Kaposi 's sarcoma marker lesion within 30 day study entry . Prior Treatment : Excluded : Irradiation Kaposi 's sarcoma marker lesion within 30 day study entry . Alcohol consumption strongly discourage .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Bleomycin</keyword>
</DOC>